These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28283376)

  • 1. Navigating the evolving therapeutic landscape in advanced prostate cancer.
    Crawford ED; Petrylak D; Sartor O
    Urol Oncol; 2017 May; 35S():S1-S13. PubMed ID: 28283376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
    Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
    Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state of castration-resistant prostate cancer.
    Petrylak DP
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H; Garcia JA
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.
    Tilki D; Evans CP
    Can J Urol; 2014 Apr; 21(2 Supp 1):7-13. PubMed ID: 24775718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current androgen receptor antagonists under investigation for resistant prostate cancer.
    Nigro MC; Mollica V; Marchetti A; Cheng M; Rosellini M; Montironi R; Cheng L; Massari F
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):191-202. PubMed ID: 34928193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
    Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
    Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy.
    Kim Y; Park YH; Lee JY; Choi IY; Yu H
    BMC Med Inform Decis Mak; 2016 Jul; 16 Suppl 1(Suppl 1):63. PubMed ID: 27453983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE; Antonarakis ES
    Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer.
    Stangl-Kremser J; Lemberger U; Hassler MR; Bruchbacher A; Ilijazi D; Garstka N; Kramer G; Haitel A; Abufaraj M; Shariat SF
    Clin Genitourin Cancer; 2019 Oct; 17(5):389-394. PubMed ID: 31331867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castration-resistant prostate cancer: AUA Guideline.
    Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
    J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.